Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition

Janus kinase (JAK) inhibitors have emerged as an effective class of therapies for various inflammatory diseases such as rheumatoid arthritis (RA). JAK inhibitors function intracellularly by modulating the catalytic activity of JAKs and disrupting the receptor‐mediated signaling of multiple cytokines...

Descripción completa

Detalles Bibliográficos
Autores principales: Dowty, Martin E., Lin, Tsung H., Jesson, Michael I., Hegen, Martin, Martin, David A., Katkade, Vaibhav, Menon, Sujatha, Telliez, Jean‐Baptiste
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857076/
https://www.ncbi.nlm.nih.gov/pubmed/31832202
http://dx.doi.org/10.1002/prp2.537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857076/
https://www.ncbi.nlm.nih.gov/pubmed/31832202
http://dx.doi.org/10.1002/prp2.537

Ejemplares similares